With an ageing population, unhealthy lifestyles and pollution, China has a world-leading incidence of cancer, with 4.3m cases diagnosed in 2015, twice the 2000 figure. That makes recruiting patients for trials easier and is potentially a huge source of demand. Recently, immunotherapy as a tumor treatment has come to the forefront because of the significant successes of therapies using immune checkpoint antibodies and chimeric antigen receptor modified T (CAR-T) cells. Research into Car-T in China has exploded in recent years. There are currently 116 clinical trials registered in the country, according to a US government database, compared with 96 in the US and 15 in Europe, giving it a lead that would have been unthinkable when the treatment was first discovered.
The success of such novel therapies depends heavily on extensive knowledge of individual patients, for which high-quality biomarkers are especially important. NGS and big data are accelerating the biomarker innovation. Current diagnostic approaches often fall short, due in large part to the complexity of the biology driving therapy responsiveness. As such, the biopharma industry is exploring many emerging approaches covering tumor, immune and even microbiome-related pathways and biomarkers.
Riding on the success of the last annual event, 3nd Annual Precision Medicine and Immuno-Oncology China Summit (PMIO 2020) is dedicated to building a premium networking platform focused on the clinical translation of precision medicine, IO and CAR-T therapies to the market in China and globally, ensuring affordability and accessibility to all those in need.
Bringing together decision makers across C level management, oncology clinicians, and top researchers in drug discovery, clinical trials and immuno-oncology sectors, this two day interactive show will provide you the opportunity to take home cutting edge strategies, case study examples, and regulatory guidelines with rich information on latest advances in NGS, Cancer immunotherapy, Liquid biopsy, Big Data and AI research, Companion Diagnostics, CRISPR-Based Gene Editing in Precision Medicine etc.
Join PMIO China 2020 with over 500+ leaders in therapeutic drug development in China, US and EU etc to discuss the latest clinical data emerging in Asia focusing the CD19 and novel targets beyond being utilized for solid tumor indications and multiple diagnostic modalities and biomarkers for immunotherapy. And also discuss with opinion leaders in China for the cutting edge technologies being used to automate CAR-T manufacturing for CoGs reduction and off-the-shelf novel therapy development with application of genome editing and immune regulation.